340B Advocacy Alliance Bulletin
The AHA 340B Advocacy Alliance Nov. 17 at 3 p.m. ET will host a special call for AHA 340B hospital members to provide an update on the latest activity on the 340B Drug Pricing Program.
A federal district court judge in Indiana Friday agreed with the government’s contention that the 340B statute would permit the Department of Health and Human Services to require that the drug company Eli Lilly offer 340B discounts for drugs distributed by hospitals through community pharmacies,…
The AHA and five other groups late Friday expressed continued support for the 340B drug pricing program and strongly encouraged Congress to protect the program as it considers broader changes to the nation’s health care system as part of a legislative package under reconciliation.
HRSA Refers Drug Companies for Enforcement Regarding 340B Community Pharmacy Actions
In comments on OPPS proposed rule, AHA continues to oppose 340B cuts The AHA continues to oppose the Centers for Medicare & Medicaid Services’ deep payments cuts to certain 340B hospitals, the association told the agency as part of its comments on the calendar year 2022 outpatient prospective…
Advocacy Alliance Bulletin
The AHA last week urged congressional leaders to provide temporary relief for any hospitals participating in the 340B Drug Pricing Program that had to leave the program due to changes in their patient mix as a result of the COVID-19 pandemic.
The AHA today urged the Supreme Court of the United States to reverse the 2020 federal appeals court decision that upheld the authority of the Department of Health and Human Services to significantly cut payments to certain hospitals that participate in the 340B Drug Pricing Program.
The Centers for Medicare & Medicaid Services July 19 released its calendar year 2022 outpatient prospective payment system/ambulatory surgical center proposed rule.
Congress is currently considering legislation that would provide temporary relief for any hospitals participating in the 340B program that had to leave the program due to patient mix changes as a result of the COVID-19 pandemic.